Quincy Bioscience receives investment
This article was originally published in The Tan Sheet
Executive SummaryA capital infusion from the investment group DaneVest Tech Fund I will help Quincy Bioscience market its "novel" dietary supplement Prevagen, the Madison, Wis.-based biotech announces Aug. 25. Quincy launched the brain cell protection supplement in 2007 and says the unquantified investment "will accelerate our goal to make Prevagen a national brand" (1"The Tan Sheet" Aug. 10, 2009). Prevagen's active ingredient apoaequorin comes from jellyfish and is a calcium-binding protein that helps buffer excess calcium from damaging aging neurons, Quincy says
You may also be interested in...
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.